Targeting RAS Mutant Cancer

Before registering, please click here to update your profile. The rate you pay is partially BASED ON YOUR PROFILE INFORMATION.

Note: You must login to register. The "Register" button to the right will become active once you login using an existing account or once you create a new nonmember account.

Targeting RAS-Driven Cancers

Dec. 9-12, 2018
Hilton San Diego Bayfront
San Diego, California

Conference Cochairs
Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Gideon Bollag, Plexxikon, Inc., Berkeley, California
Karen M. Cichowski, Harvard Medical School, Brigham & Women's Hospital, Boston, Massachusetts
Shiva Malek, Genentech, Inc., South San Francisco, California

Mutations in RAS genes, KRAS in particular, are present in 30% of all cancers. As a result of key therapeutic advances as well as improvements in areas of basic research due to updated technologies, the last 5 years have witnessed an invigoration in the field. Therapeutic discoveries directed at targeting KRAS, as well as effectors in artificial membranes becoming more accessible, have helped KRAS re-emerge as a ?druggable? target.

This conference will focus on potentially druggable aspects of KRAS biology, including emergent areas such as systems approaches and immunotherapy. The conference will leverage the substantial gains in recent years in the understanding of proximal targeting of KRAS to provide a comprehensive and in-depth forum, and will include field leaders in all aspects of KRAS biology to allow for direct engagement between industry and academia.

Start Date: Sunday, December 9, 2018
End Date: Wednesday, December 12, 2018
Address: Hilton San Diego Bayfront
San Diego, CA

You must log on
or create a new account
before continuing through the checkout process.

Find an existing account.